Top

Published in:

Open Access 01-05-2014 | Hepatobiliary Tumors

The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases

Authors: Kazuya Nakagawa, MD, Kuniya Tanaka, MD, PhD, Kazunori Nojiri, MD, PhD, Takafumi Kumamoto, MD, PhD, Kazuhisa Takeda, MD, PhD, Michio Ueda, MD, PhD, Itaru Endo, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2014

Abstract

Background

The inflammation-based Glasgow prognostic score (GPS) has been demonstrated to be prognostic for various tumors. We investigated the value of the modified GPS (mGPS) for the prognosis of patients undergoing curative resection for colorectal liver metastases (CRLM).

Methods

A total of 343 patients were enrolled onto this study. The mGPS was calculated as follows: mGPS-0, C-reactive protein (CRP) ≤10 mg/L; mGPS-1, CRP >10 mg/L and albumin ≥35 g/L; and mGPS-2, CRP >10 mg/L and albumin <35 g/L. Prognostic significance was retrospectively analyzed by univariate and multivariate analyses.

Results

Of the 343 patients, 295 (86.0 %) were assigned to mGPS-0, 33 (9.6 %) to mGPS-1, and 15 (4.4 %) to mGPS-2. The median disease-free survival of patients with mGPS-0, -1, and -2 was 18.3, 15.5, and 5.2 months, respectively. The median cancer-specific survival (CSS) of patients with mGPS-0, -1, and -2 was 89.5, 62.2, and 25.8 months, respectively. The CSS of patients with mGPS-0 was significantly longer than that of patients with mGPS-2. Multivariate analysis revealed a significant association between cancer-related postoperative mortality and mGPS and carcinoembryonic antigen level.

Conclusions

The preoperative mGPS is a useful prognostic factor for postoperative survival in patients undergoing curative resection for CRLM.

Rudy DR, Zdon MJ. Update on colorectal cancer. Am Fam Physician. 2000;61:1759–70, 1773–4.

Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006;107:1711–42.PubMedCrossRef

Kawasaki S, Makuuchi M, Kakazu T, et al. Resection for multiple metastatic liver tumors after portal embolization. Surgery. 1994;115:674–7.PubMed

Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.PubMedCentralPubMedCrossRef

Tanaka K, Matsuyama R, Takeda K, Matsuo K, Nagano Y, Endo I. Aggressive liver resection including major-vessel resection for colorectal liver metastases. World J Hepatol. 2009;1:79–89.PubMedCentralPubMedCrossRef

Tanaka K, Kumamoto T, Nojiri K, Takeda K, Ichikawa Y, Endo I. Timing of two-stage liver resection during chemotherapy for otherwise unresectable colorectal metastases. World J Surg. 2012;36:1832–41.PubMedCrossRef

Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–22.PubMedCentralPubMedCrossRef

Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S. Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery. 2008;143:259–70.PubMedCrossRef

de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626–37.PubMed

10.

Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.PubMedCrossRef

11.

Giuliante F, Ardito F, Vellone M, et al. Role of the surgeon as a variable in long-term survival after liver resection for colorectal metastases. J Surg Oncol. 2009;100:538–45.PubMedCrossRef

12.

de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1,669 patients. Ann Surg. 2009;250:440–8.PubMed

13.

Muratore A, Ribero D, Zimmitti G, Mellano A, Langella S, Capussotti L. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol. 2010;17:1324–9.PubMedCrossRef

14.

Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335–8.PubMedCrossRef

15.

McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.PubMedCrossRef

16.

Koike Y, Miki C, Okugawa Y, et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol. 2008;98:540–4.PubMedCrossRef

17.

Jagdev SP, Gregory W, Vasudev NS, et al. Improving the accuracy of preoperative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer. 2010;103:1649–56.PubMedCentralPubMedCrossRef

18.

Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63.PubMedCrossRef

19.

Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.PubMedCrossRef

20.

Wong VK, Malik HZ, Hamady ZZ, et al. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer. 2007;96:222–5.PubMedCentralPubMedCrossRef

21.

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90:1704–6.PubMedCentralPubMed

22.

Forrest LM, McMillan DC, McArdle CS, et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;92:1834–6.PubMedCentralPubMedCrossRef

23.

Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer. 2004;48:171–3.PubMedCrossRef

24.

Brown DJ, Milroy R, Preston R, McMillan DC. The relationship between an inflammation based prognositic score (GPS) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol. 2007;60:705–8.PubMedCentralPubMedCrossRef

25.

Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94:637–41.PubMedCentralPubMed

26.

Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6:450–3.PubMedCrossRef

27.

Read JA, Choy ST, Beale PJ, Clarke SJ. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer. 2006;55:78–85.PubMedCrossRef

28.

Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109:205–12.PubMedCrossRef

29.

Ishizuka M, Nagata H, Takagi K, Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 2009;250:268–72.PubMedCrossRef

30.

McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881–6.PubMedCrossRef

31.

Ishizuka M, Kita J, Shimoda M, et al. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Oncol. 2009;100:38–42.PubMedCrossRef

32.

Kobayashi T, Teruya M, Kishiki T, et al. Elevated C-reactive protein and hypoalbuminemia measured before resection of colorectal liver metastases predict postoperative survival. Dig Surg. 2010;27:285–90.PubMedCrossRef

33.

Crozier JE, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer. Am J Surg. 2009;197:544–9.PubMedCrossRef

34.

Richards CH, Leitch EF, Horgan PG, Anderson JH, McKee RF, McMillan DC. The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2010;103:1356–61.PubMedCentralPubMedCrossRef

35.

Roxburgh CS, Platt JJ, Leitch EF, Kinsella J, Horgan PG, McMillan DC. Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol. 2011;18:997–1005.PubMedCrossRef

36.

Lai CC, You JF, Yeh CY, et al. Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis. 2011;26:473–81.PubMedCrossRef

37.

Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92:651–4.PubMedCentralPubMedCrossRef

38.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCentralPubMedCrossRef

39.

Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26:1348–53.PubMedCrossRef

40.

Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg. 2004;139:1168–72.PubMedCrossRef

41.

Hill CR, Chagpar RB, Callender GG, et al. Recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol. 2012;19:139–44.PubMedCrossRef

42.

D’Angelica M, Kornprat P, Gonen M, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18:1096–103.PubMedCrossRef

43.

Yang J, Wezeman M, Zhang X, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007;12:252–65.PubMedCrossRef

44.

Xavier P, Belo L, Beires J, et al. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet. 2006;273:227–31.PubMedCrossRef

45.

Tanigawa N, Amaya N, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997;15:826–32.PubMed

46.

Fondevila C, Metges JP, Fuster J, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004;90:206–15.PubMedCentralPubMedCrossRef

47.

Registry of hepatic metastases. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery. 1988;103:278–88.

48.

Heslin MJ, Medina-Franco H, Parker M, Vickers SM, Aldrete J, Urist MM. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. Arch Surg. 2001;136:318–23.PubMedCrossRef

Title: The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases
Authors: Kazuya Nakagawa, MD
Kuniya Tanaka, MD, PhD
Kazunori Nojiri, MD, PhD
Takafumi Kumamoto, MD, PhD
Kazuhisa Takeda, MD, PhD
Michio Ueda, MD, PhD
Itaru Endo, MD, PhD
Publication date: 01-05-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 5/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3342-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

In Memoriam: Donald L. Morton, MD (1934–2014): An Icon in Surgical Oncology

The Effect of Elevated Body Mass Index on Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Does Extracapsular Extension Impact the Prognosis of Papillary Thyroid Microcarcinoma?

The End of the Beginning: Society of Surgical Oncology 2013 Presidential Address

Prognostic Factors and Causes of Death in Patients Cured of Esophageal Cancer

Cancer Recurrence: An Important but Missing Variable in National Cancer Registries